[144] Veracyte, Inc. SEC Filing

Rhea-AI Filing Summary

Veracyte, Inc. (VCYT) notice reports a proposed sale of 7,667 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $234,763.54 and an approximate sale date of 09/04/2025. The filing shows the shares were acquired as Restricted Stock Units from the issuer on 09/02/2025 and payment/vesting is recorded as 09/02/2025. The issuer's total shares outstanding is listed as 78,671,588. The filer reports no securities sold by the same person in the past three months. The notice includes the required representation that the seller does not possess any undisclosed material adverse information regarding the issuer.

Positive

• Complete disclosure of transaction details including broker, share count, aggregate market value, acquisition date, and sale date
• No reported sales in the past three months for the person whose account is to be sold

Negative

• Proposed sale occurs two days after acquisition (acquired 09/02/2025, approx sale 09/04/2025), indicating a very short holding period

Insights

Securities Analyst

TL;DR Transaction discloses a small proposed sale of vested RSUs executed via Morgan Stanley two days after vesting.

The filing documents a routine insider sale: 7,667 shares acquired as restricted stock units on 09/02/2025 and scheduled for sale on 09/04/2025 through Morgan Stanley Smith Barney LLC. The aggregate market value is $234,763.54 and the issuer has 78,671,588 shares outstanding. No sales by this person in the prior three months are reported, which suggests this is an isolated disposition rather than part of a sequence of recent sales. The filing also includes the standard attestation about lack of undisclosed material information.

Corporate Governance Expert

TL;DR Filing appears procedural and compliant, disclosing timing and broker details for an RSU-derived sale.

The notice contains required elements: class of security, broker name and address, number of shares, aggregate market value, outstanding shares, acquisition date, nature of acquisition (Restricted Stock Units), and representation regarding material nonpublic information. The absence of prior sales in the past three months is explicitly stated. No plan adoption date or 10b5-1 instruction date is provided in the remarks, so the sale appears to be a simple notice of proposed sale rather than tied to a publicly documented trading plan within this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7667	234763.54	78671588	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Restricted Stock Units	Issuer			7667	09/02/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares of Veracyte (VCYT) are being offered for sale?

The filing reports a proposed sale of 7,667 shares of Veracyte common stock.

When were the shares acquired and how were they acquired?

The shares were acquired on 09/02/2025 as Restricted Stock Units from the issuer.

What is the aggregate market value of the proposed sale?

The aggregate market value is reported as $234,763.54.

Through which broker will the sale be executed?

The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Is there any record of prior sales by this person in the past three months?

The filing states Nothing to Report for securities sold during the past three months by the person whose account is to be sold.

How many shares does Veracyte have outstanding according to the filing?

The filing lists 78,671,588 shares outstanding.